Wave Life Sciences Ltd. (FRA:1U5)

Market Cap	1.20B +47.3%
Revenue (ttm)	36.39M -60.5%
Net Income	-174.07M
EPS	-1.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	130
Open	5.95
Previous Close	5.95
Day's Range	5.95 - 5.95
52-Week Range	4.80 - 17.80
Beta	n/a
RSI	37.75
Earnings Date	Apr 28, 2026

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 317
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1U5

Financial Performance

In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.

Financial numbers in USD